LexDanaLexDanabeta
Inventor

Barbara Kure Klein

Inventor
St. Louis, MO, US

Overview

38→
Patents
1996–2012
Patent span
Human necessities
Primary field (CPC A)

Patents· 38 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes28%
C07KPeptides28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%
C12NMicroorganisms or enzymes8%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8%
A61LMethods or apparatus for sterilising materials or objects in general3%
A61CDentistry2%
A61QSpecific use of cosmetics or similar toiletry preparations2%
Y10TTechnical subjects covered by former us classification2%
C12YEnzymes1%
PatentTitleYear
8,231,894'Antimicrobial and immunostimulating composition'20127,348,021'Immunostimulating coating for surgical devices'20087,091,319'IL-3 variant hematopoiesis fusion protein'20066,730,303'Fused G-CSF and IL-3 proteins and uses thereof'20046,541,678'Immunostimulating coating for surgical devices'20036,479,261'Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells'20026,458,931'Interleukin-3 (IL-3) multiple mutation polypeptides'20026,440,407'Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptides'20026,436,387'Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins'20026,413,509'Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors'20026,403,076'Compositions for increasing hematopoiesis with interleukin-3 mutants'20026,379,662'Co-administration of interleukin-3 mutant polypeptides with CSF\'s for multi-lineage hematopoietic cell production'20026,361,977'Methods of using multivariant IL-3 hematopoiesis fusion protein'20026,361,976'Co-administration of interleukin-3 mutant polypeptides with CSF\'S for multi-lineage hematopoietic cell production'20026,358,505'G-CSF receptor agonists'20026,168,799'.beta.-D-glucan topical composition'20016,153,183'Co-administration of interleukin-3 mutant polypeptides with CSF\'s or cytokines for multi-lineage hematopoietic cell production'20006,133,506'Keto-acyl-(ACP) reductase promoter from cuphea lanceolata'20006,132,991'Human interleukin-3 (IL-3) variant fusion proteins'20006,100,070'G-CSF receptor agonists'20006,093,395'Co-administration of interleukin-3 mutant polypeptides with CSF\'s for multi-lineage hematopoietic cell production'20006,074,639'Ex vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteins'20006,066,318'Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors'20006,060,047'Co-administration of interleukin-3 mutant polypeptides with CSF\'s for multi-lineage hematopoietic cell production'20006,057,133'Multivariant human IL-3 fusion proteins and their recombinant production'20006,051,217'Therapeutic uses of interleukin-3 (IL-3) multiple mutation polypeptides'20006,030,812'Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors'20006,022,535'Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors'20005,997,857'Co-administration of interleukin-3 mutants with colony stimulating factors'19995,997,860'Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines'19995,980,918'.beta.-D-glucan topical composition'19995,858,347'Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors'19995,772,992'Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors'19985,738,849'Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them'19985,677,149'Interleukin-3 (IL-3) mutant polypeptides and their recombinant production'19975,604,116'Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods'19975,543,141'Therapeutic methods using interleukin-3 (IL-3) human/murine hybrid polypeptides'19965,501,962'Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same'1996

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1996–2002Patents assigned to SEARLE & CO (22)· patent assignee history
1996–2006Based in St. Louis, MO, US· patent location history
1997–2002Based in Town and Country, MO, US· patent location history
1999–2012Patents assigned to BRENNEN MEDICAL INC (4)· patent assignee history
1999–2001Based in Lindstrom, MN, US· patent location history
2000Based in Cologne, DE· patent location history
2002–2004Patents assigned to PHARMACIA CORP (2)· patent assignee history
2003–2012Based in North Oaks, MN, US· patent location history
2006Patents assigned to ABRAMS MARK ALLEN (1)· patent assignee history
2006Patents assigned to BAUER S CHRISTOPHER (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SEARLE & CO221996–2002
BRENNEN MEDICAL INC41999–2012
PHARMACIA CORP22002–2004
ABRAMS MARK ALLEN12006
BAUER S CHRISTOPHER12006
Locations
LocationPatentsSpan
St. Louis, MO, US281996–2006
Town and Country, MO, US41997–2002
North Oaks, Minnesota, US32003–2012
Lindstrom, Minnesota, US21999–2001
Cologne, DE12000